New Immunotherapy Options in Acute Lymphoblastic Leukemia: Implications for Nurses—Downloadable Webcast

In this on-demand Webcast, Sara Tinsley, PhD, ARNP, AOCN, reviews nursing strategies and key data on the latest immunotherapies for ALL.
person default
Mary Beth Rios, RN, CCRP
Program Director
person default
Mary Alma Welch, PAC
Program Director
person default
Sara Tinsley, PhD, ARNP, AOCN
Registered Nurses: 1.0 Nursing contact hour
Released: March 1, 2019 Expiration: February 29, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain to patients with ALL the limitations of standard treatment and potential benefit for novel immunotherapy options
  • Discuss the relative merits of single-agent immunotherapies vs antibody–drug conjugates vs CAR T-cell therapy for the treatment of ALL
  • Query patients for their preferences which may have a direct impact on choice of treatment for their ALL
  • Apply preventive as well as management strategies for treatment-related toxicities associated with novel therapeutics in ALL, including veno-occlusive disease and cytokine-release syndrome
  • Communicate effectively with patients to involve them in the prevention and management of treatment-related toxicities associated with novel therapeutics in ALL

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Mary Beth Rios, RN, CCRP

Director, Research Planning and Development
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Mary Beth Rios, RN, CCRP, has no real or apparent conflicts of interest to report.
Mary Alma Welch, PAC

Manager, Advanced Practice Providers
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Mary Alma Welch, PAC, has no real or apparent conflicts of interest to report.

Faculty

Sara Tinsley, PhD, ARNP, AOCN

Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Sara Tinsley, PhD, ARNP, AOCN, has no real or apparent conflicts of interest to report.

Staff

Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no real or apparent conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees from non-CME services from Harmony Biosciences, Saluda Medical, and Shionogi.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncology nurses and other healthcare providers who care for patients with acute lymphoblastic leukemia.

Goal

The goal of this activity is to improve oncology nurses’ ability to educate, partner in shared decision making with, and optimally care for patients with acute lymphoblastic leukemia.

Nursing Continuing Education

Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 01, 2019, through February 29, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Farhad Ravandi, MD, discuss important presentations in hematologic malignancies from the virtual ASCO 2020 as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji Kumar, MD Farhad Ravandi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 23, 2020 Expired: September 22, 2021

Commentary by Jesús F. San-Miguel, MD, PhD, on treating patients with myeloma who experience biochemical relapse from Clinical Care Options (CCO)

Jesús F. San-Miguel, MD, PhD Released: September 22, 2020

Commentary from Danielle M. Brander, MD, on the importance of prognostic testing of key markers in patients with CLL, as reported by Clinical Care Options (CCO)

Danielle Brander, MD Released: September 22, 2020

Downloadable clinical resource from CCO includes a proposed 2020 treatment algorithm for myeloma

Shaji Kumar, MD Released: September 22, 2020
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by educational grants from
Amgen
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?